Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report

Changing ALK-TKI mechanisms of resistance in re-biopsies of ALK-rearranged NSCLC: ALK mutations followed by SCLC-like histologic transformation: A case report

Anaplastic lymphoma kinase (ALK) inhibitors are the recommended treatment of ALK-rearranged non-small cell lung cancer but are prone to eventual drug resistance.Herein we report a 45-year-old Asian woman diagnosed with EML4-ALK rearranged lung adenocarcinoma. Small cell lung cancer-like phenotypic t...

Full description

Bibliographic Details
Main Authors: Qiong He, Xinmin Yu, Junrong Yan, Xun Shi, Hongming Pan
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:Heliyon
Subjects:
NSCLC
Histologic transformation
ALK-TKI
Resistance mechanism
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844024080617

Internet

http://www.sciencedirect.com/science/article/pii/S2405844024080617

Similar Items